[go: up one dir, main page]

WO2003065981A3 - Therapeutic use for lp229, in particular for wound healing - Google Patents

Therapeutic use for lp229, in particular for wound healing Download PDF

Info

Publication number
WO2003065981A3
WO2003065981A3 PCT/US2002/000487 US0200487W WO03065981A3 WO 2003065981 A3 WO2003065981 A3 WO 2003065981A3 US 0200487 W US0200487 W US 0200487W WO 03065981 A3 WO03065981 A3 WO 03065981A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
wound healing
therapeutic use
skin
immunodeficiencies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000487
Other languages
French (fr)
Other versions
WO2003065981A2 (en
Inventor
Josef Georg Heuer
Kristine Kay Kirkly
Eric Wen Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU2002365236A priority Critical patent/AU2002365236A1/en
Priority to EP02805684A priority patent/EP1545591A2/en
Priority to US10/250,959 priority patent/US20040072745A1/en
Anticipated expiration legal-status Critical
Publication of WO2003065981A2 publication Critical patent/WO2003065981A2/en
Publication of WO2003065981A3 publication Critical patent/WO2003065981A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods of use are provided for the treatment or prevention of poor healing or chronic wounds, skin diseases, sepsis, inflammation, immunodeficiencies, autoimmune diseases, infectious diseases, allergic diseases, and malignancies, particularly those disorders associated with the skin, by administering an LP229 polypeptide, protein, or epitope-recognizing antibody thereof to a patient in need of such therapy.
PCT/US2002/000487 2001-01-18 2002-01-09 Therapeutic use for lp229, in particular for wound healing Ceased WO2003065981A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002365236A AU2002365236A1 (en) 2001-01-18 2002-01-09 Therapeutic use for lp229, in particular for wound healing
EP02805684A EP1545591A2 (en) 2001-01-18 2002-01-09 Therapeutic use for lp229, in particular for wound healing
US10/250,959 US20040072745A1 (en) 2002-01-09 2002-01-09 Therapeutic methods of use for lp229

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26245801P 2001-01-18 2001-01-18
US60/262,458 2001-01-18
US32523301P 2001-09-27 2001-09-27
US60/325,233 2001-09-27

Publications (2)

Publication Number Publication Date
WO2003065981A2 WO2003065981A2 (en) 2003-08-14
WO2003065981A3 true WO2003065981A3 (en) 2005-04-07

Family

ID=27737161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000487 Ceased WO2003065981A2 (en) 2001-01-18 2002-01-09 Therapeutic use for lp229, in particular for wound healing

Country Status (3)

Country Link
EP (1) EP1545591A2 (en)
AU (1) AU2002365236A1 (en)
WO (1) WO2003065981A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042201A2 (en) * 1999-01-11 2000-07-20 Incyte Pharmaceuticals, Inc. Human peptidases
WO2002026801A2 (en) * 2000-09-28 2002-04-04 Eli Lilly And Company Secreted proteins and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042201A2 (en) * 1999-01-11 2000-07-20 Incyte Pharmaceuticals, Inc. Human peptidases
WO2002026801A2 (en) * 2000-09-28 2002-04-04 Eli Lilly And Company Secreted proteins and their uses

Also Published As

Publication number Publication date
EP1545591A2 (en) 2005-06-29
AU2002365236A1 (en) 2003-09-02
WO2003065981A2 (en) 2003-08-14
AU2002365236A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
CY2014005I1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE THERAPEUTIC TREATMENT OF SKIN DISORDERS
CA2549550A1 (en) Botulinum toxin therapy for skin disorders
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
ID24901A (en) METHOD OF TREATMENT OF HIGH COAGAGULATION OR DEFICIENCY OF PROTEIN C OBTAINED
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
WO2003093293A3 (en) Peptide antagonists of tgf-beta family members and therapeutic uses thereof
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
WO2003039444A3 (en) Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
ATE460431T1 (en) NON-NEUTRALIZING ANTI-APC ANTIBODIES
IL181286A0 (en) Methods of healing wounds by administering human il-18
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
WO2002051379A3 (en) Thixotropic nasal spray
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
Szor et al. Use of magnet therapy to heal an abdominal wound: a case study
AU2024261970A1 (en) Sialylated human factor h protein and therapeutic use thereof
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
WO2004081046A3 (en) Human monoclonal antibodies against apociii and their use in the therapy of atherosclerosis
WO2003065981A3 (en) Therapeutic use for lp229, in particular for wound healing
HUP0400340A2 (en) Methods for reducing immunogenicity of polypeptides
WO2003051378A3 (en) Pharmaceutical composition for topical treatment of skin disorders and skin wounds
CA2421026A1 (en) Viral inhibition by n-docosanol
EP1661578A4 (en) MEANS FOR THE PREVENTION AND HEALING OF SKIN DISEASES WITH HUMAN RECOMBINANT HGF

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2002805684

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10250959

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWW Wipo information: withdrawn in national office

Ref document number: 2002805684

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002805684

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP